Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Wachstum
Das Unternehmen befindet sich in einer Wachstumsphase, wobei das aktuelle Jahreseinkommen insgesamt 6.20K USD beträgt.
Angemessen bewertet
Die aktuelle PE1 des Unternehmens liegt bei -0.892, im mittleren 3-Jahres-Perzentilbereich.
Institutionelle Käufe
Die neuesten institutionellen Bestände sind 555.77K Aktien, was eine Steigerung von 39.35% im Vergleich zum Vorquartal darstellt.